RecruitingRecruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381 · Jazz Pharmaceuticals
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
About this study
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Eligibility criteria
Inclusion Criteria:
1. Has newly diagnosed Stage II or III histologically confirmed invasive breast carcinoma.
2. Has histologically confirmed HER2-positive breast cancer
3. Has a known hormone receptor (HR) status of the primary tumor
4. Participants with multifocal or multicentric disease are eligible if the largest tumor (which must be larger than or equal to 2 cm in diameter) is HER2-positive, and the treating physician has determined the participant should be treated as HER2-positive.
5. Agrees to undergo a mastectomy or breast conserving surgery (BCS) after neoadjuvant therapy.
6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. Adequate organ function
8. Has an LVEF ≥ 50% as determined by either ECHO or MUGA obtained within 6 weeks prior to randomization.
9. Adequate contraceptive precautions
10. Participants with known HIV are eligible unless:
1. CD4+ T Cell count is less than or equal to 350 microliters (uL)
2. Detectable viral load, or
3. Receiving protease inhibitors or cobicistat
Exclusion Criteria:
1. Has Stage IV (metastatic) breast cancer.
2. Has bilateral breast cancer.
3. Has a history of any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator, could affect the participant's involvement in the study.
4. Has uncontrolled hypertension
5. Has significant symptoms from peripheral neuropathy
6. Has an active uncontrolled infection
7. Has a history of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in the drug formulation of zanidatamab or other study interventions.
8. Known active hepatitis B or C infection.
9. Has another malignancy diagnosed within the last 5 years. Exceptions include previously treated non melanomatous skin cancers, carcinoma in-situ, and melanoma in-situ. Participants with prior ipsilateral ductal carcinoma in situ (DCIS) or invasive breast cancer are not eligible.
10. Was treated with surgery, chemotherapy, anti-HER2 therapy, radiation therapy, endocrine therapy, or experimental therapy for invasive breast cancer
11. Is planning to receive concurrent therapy with any other investigational agent or anti-cancer therapy not specified in the protocol
12. Receipt of a live vaccine within 4 weeks prior to enrollment
13. Has a known hypersensitivity to any components of the study interventions, including chemotherapy
Study design
Enrollment target: 125 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-09-24
Estimated completion: 2030-05-02
Last updated: 2026-11-17
Interventions
Drug: ZanidatamabDrug: PaclitaxelDrug: DocetaxelDrug: CarboplatinDrug: TrastuzumabDrug: Pertuzumab
Primary outcomes
- • Number of participants with pCR (Up to 8 months)
Sponsor
Jazz Pharmaceuticals · industry
With: Jazz Pharmaceuticals Ireland Limited
Contacts & investigators
ContactClinical Trial Disclosure & Transparency · contact · ClinicalTrialDisclosure@JazzPharma.com · 215-832-3750
All locations (60)
Oncology InstituteRecruiting
Long Beach, California, United States
Cancer & Blood Research CenterRecruiting
Los Alamitos, California, United States
Cedars Sinai Medical CenterRecruiting
Los Angeles, California, United States
Rocky Mountain Cancer CentersRecruiting
Denver, Colorado, United States
Holy Cross HospitalRecruiting
Fort Lauderdale, Florida, United States
The Oncology InstituteRecruiting
Lakeland, Florida, United States
The University of Chicago Medical CenterRecruiting
Chicago, Illinois, United States
Accellacare of McFarlandRecruiting
Ames, Iowa, United States
LSU Health Sciences CenterRecruiting
Shreveport, Louisiana, United States
New England Cancer SpecialistsRecruiting
Scarborough, Maine, United States
Maryland Oncology HematologyRecruiting
Laurel, Maryland, United States
Dana Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
Henry Ford HospitalRecruiting
Detroit, Michigan, United States
Cancer Partners of NebraskaRecruiting
Lincoln, Nebraska, United States
Nebraska Cancer SpecialistsRecruiting
Omaha, Nebraska, United States
Astera Cancer Care (Formerly Regional Cancer Care Associates)Withdrawn
East Brunswick, New Jersey, United States
Medical Oncology Hematology AssociatesRecruiting
Newark, New Jersey, United States
The University of New MexicoRecruiting
Albuquerque, New Mexico, United States
Hematology Oncology Associates of Central New YorkRecruiting
Camillus, New York, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
University of North Carolina Lineberger Comprehensive Cancer CenterRecruiting
Chapel Hill, North Carolina, United States
Levine CancerRecruiting
Charlotte, North Carolina, United States
Sarah Cannon Research Institute (Nashville)Recruiting
Nashville, Tennessee, United States
Vanderbilt University Medical CenterRecruiting
Nashville, Tennessee, United States
Texas Oncology DFWRecruiting
Dallas, Texas, United States
The University of Texas Southwestern Medical CenterRecruiting
Dallas, Texas, United States
Texas Oncology Gulf CoastRecruiting
Houston, Texas, United States
UT Health San Antonio, Mays Cancer CenterRecruiting
San Antonio, Texas, United States
Virginia Cancer SpecialistsRecruiting
Fairfax, Virginia, United States
Virginia Oncology AssociatesRecruiting
Norfolk, Virginia, United States
Shenandoah OncologyRecruiting
Winchester, Virginia, United States
Northwest Medical SpecialtiesRecruiting
Puyallup, Washington, United States
Northwest Cancer SpecialistsRecruiting
Vancouver, Washington, United States
University of WisconsinRecruiting
Madison, Wisconsin, United States
Hämatologie-Onkologie ZentrumRecruiting
Augsburg, Germany
Staedtisches Klinikum DessauRecruiting
Dessau, Germany
Klinikum Esslingen GmbHRecruiting
Esslingen am Neckar, Germany
Mammazentrum Hamburg MVZ GbRRecruiting
Hamburg, Germany
Institut Fuer Versorgungsforschung In Der Onkologie GbRRecruiting
Koblenz, Germany
Marien Hospital WittenRecruiting
Witten, Germany
Klinikum Worms gGmbHRecruiting
Worms, Germany
Ospedale San RaffaeleRecruiting
Milan, Lombardy, Italy
AOU di BolognaRecruiting
Bologna, Italy
Policlinico San MartinoRecruiting
Genoa, Italy
Istituto Europeo di OncologiaRecruiting
Milan, Italy
Humanitas Ist.Clinico CataneseRecruiting
Misterbianco, Italy
IRCCS San Gerardo dei TintoriRecruiting
Monza, Italy
IRCCS Fondazione PascaleRecruiting
Naples, Italy
University of Campania Luigi VanvitelliRecruiting
Naples, Italy
Hospital Universitario San CecilioRecruiting
Granada, Andalusia, Spain
Álvaro Cunqueiro HospitalRecruiting
Vigo, Galicia, Spain
Hospital Universitario Vall d'HebronRecruiting
Barcelona, Spain
Hospital del MarRecruiting
Barcelona, Spain
Hospital Clinic BarcelonaRecruiting
Barcelona, Spain
Catalan Institute of Oncology Duran i ReynalsRecruiting
Barcelona, Spain
Hosp Beata María Ana de JesúsRecruiting
Madrid, Spain
Hospital Universitario Virgen de la VictoriaRecruiting
Málaga, Spain
Hospital Universitari Son EspasesRecruiting
Palma de Mallorca, Spain
Hospital Universitario Virgen MacarenaRecruiting
Seville, Spain
Hospital Clinico Universitario de ValenciaRecruiting
Valencia, Spain